CTR1 Antibody

1. Several biological properties of the GST-hNdCTR1 fusion protein were assessed. It was demonstrated that in cells, the protein was prone to oligomerization, formed inclusion bodies and displayed no toxicity. Treatment of E. coli cells with copper and silver ions reduced cell viability in a dose- and time-dependent manner PMID: 29099786
2. 11 single-nucleotide polymorphisms (SNPs) in CTR1, CTR2, ATP7A, and ATP7B were genotyped in these patients. PMID: 28737129
3. Polymorphism at CTR1 rs12686377 may be associated with toxicity from platinum-based regimens. PMID: 27797249
4. findings show that beta-elemene can block the reduction of CTR1 resulting from oxaliplatin treatment, and therefore has a synergistic anti-hepatocellular carcinoma effect with oxaliplatin by enhancing cellular uptake of oxaliplatin. PMID: 26867799
5. The transition metal ion homeostasis was disrupted in ctr1Delta300 overexpressing strains combined with a transcriptional remodeling of cellular processes. PMID: 23576094
6. functional roles for structural remodeling of the Ctr1 multimeric complex in copper transport and suggest distinct mechanisms employed by Ctr1 for copper and cisplatin transport. PMID: 17627943
7. Targeting of Ctr1p into the endocytic downregulation pathway with delivery to the vacuole clearly requires Rsp5p and ubiquitinylation of Ctr1p. PMID: 17645432
8. conformational changes in the cytosolic tail of yeast Ctr1 by copper sensing within this domain lead to the inhibition of Ctr1-mediated copper transport PMID: 19088072

Show More

Hide All

KEGG: sce:YPR124W

STRING: 4932.YPR124W